Long-Term Outcomes of Sotorasib in KRAS-G12C Non–Small-Cell Lung Cancer
1. Sotorasib showed prolonged efficacy with a median OS of 12.5 months (33% at 24 months) and an ORR of ...
1. Sotorasib showed prolonged efficacy with a median OS of 12.5 months (33% at 24 months) and an ORR of ...
1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...
1. Patients allocated to the sotorasib group reported increased progression-free survival compared to the docetaxel group. 2. Sotorasib was generally ...
1. In patients with KRAS p.G12C mutated pancreatic cancer, 21% had a partial response, and 0% had a complete response. ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.